Status:
COMPLETED
Study Of Cabozantinib Treatment In Patients With Unresectable, Locally Advanced Or Metastatic Renal Cell Carcinoma Who Progressed After Previous Treatment With Checkpoint Inhibitors
Lead Sponsor:
Ipsen
Conditions:
Locally Advanced or Metastatic Renal Cell Carcinoma
Eligibility:
All Genders
18+ years
Brief Summary
To understand the epidemiology, treatment patterns and outcomes of patients with metastatic Renal Cell Carcinoma (mRCC). Data from mRCC patients who received cabozantinib versus non-cabozantinib Tyros...
Eligibility Criteria
Inclusion
- Evidence of metastatic Renal Cell Carcinoma (mRCC) during the study period (May 01, 2016 to March 31, 2020);
- Patients who received cabozantinib or non-cabozantinib TKI regimens during identification period (May 01, 2016 to September 30, 2019);
- Patients who received CPIs, as monotherapy, or in combination with a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor (e.g. ipilimumab+nivolumab), as the latest treatment for mRCC administrated before cabozantinib or other TKI therapy;
- Patients ≥ 18 years of age as of their index date
- Patients who received care at a US Oncology Network site
- Patients with ≥ 2 visits within the US Oncology Network.
Exclusion
- Patients enrolled in a clinical trial at any time during index period
- Patients receiving treatment for another documented primary cancer diagnoses during the study period
Key Trial Info
Start Date :
January 30 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 5 2020
Estimated Enrollment :
247 Patients enrolled
Trial Details
Trial ID
NCT04353765
Start Date
January 30 2020
End Date
June 5 2020
Last Update
November 17 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
McKesson Life Sciences
The Woodlands, Texas, United States, 77380